1. Scrip
  2. >>Business

Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

 
• By Sten Stovall

US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.

Handshake
BI 860585 is a potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor. • Source: Shutterstock

Xynomic Pharmaceuticals Inc. has sealed its second in-licensing deal with Germany's Boehringer Ingelheim GMBH by acquiring exclusive, worldwide rights to develop, manufacture and commercialize BI 860585, a Phase II-ready mTORC1/2 inhibitor which the biotech wants to test in solid tumors, initially against breast cancer and colorectal cancer.

A potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor, BI 860585 has been tested in a Phase I trial with 90 patients with advanced solid tumors as single agent, in combination with with hormonal therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.